JP2013541503A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541503A5
JP2013541503A5 JP2013523380A JP2013523380A JP2013541503A5 JP 2013541503 A5 JP2013541503 A5 JP 2013541503A5 JP 2013523380 A JP2013523380 A JP 2013523380A JP 2013523380 A JP2013523380 A JP 2013523380A JP 2013541503 A5 JP2013541503 A5 JP 2013541503A5
Authority
JP
Japan
Prior art keywords
aryl
alkyl
pharmaceutical composition
heterocycle
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013523380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541503A (ja
JP5918235B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/046857 external-priority patent/WO2012019165A2/en
Publication of JP2013541503A publication Critical patent/JP2013541503A/ja
Publication of JP2013541503A5 publication Critical patent/JP2013541503A5/ja
Application granted granted Critical
Publication of JP5918235B2 publication Critical patent/JP5918235B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013523380A 2010-08-05 2011-08-05 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法 Expired - Fee Related JP5918235B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37111610P 2010-08-05 2010-08-05
US61/371,116 2010-08-05
PCT/US2011/046857 WO2012019165A2 (en) 2010-08-05 2011-08-05 Methods of inhibition of protein fucosylation in vivo using fucose analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016076930A Division JP6113887B2 (ja) 2010-08-05 2016-04-07 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法

Publications (3)

Publication Number Publication Date
JP2013541503A JP2013541503A (ja) 2013-11-14
JP2013541503A5 true JP2013541503A5 (enExample) 2014-09-25
JP5918235B2 JP5918235B2 (ja) 2016-05-18

Family

ID=45560106

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013523380A Expired - Fee Related JP5918235B2 (ja) 2010-08-05 2011-08-05 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2016076930A Expired - Fee Related JP6113887B2 (ja) 2010-08-05 2016-04-07 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2017049534A Active JP6622238B2 (ja) 2010-08-05 2017-03-15 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2019210313A Pending JP2020040974A (ja) 2010-08-05 2019-11-21 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016076930A Expired - Fee Related JP6113887B2 (ja) 2010-08-05 2016-04-07 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2017049534A Active JP6622238B2 (ja) 2010-08-05 2017-03-15 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2019210313A Pending JP2020040974A (ja) 2010-08-05 2019-11-21 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法

Country Status (21)

Country Link
US (4) US9504702B2 (enExample)
EP (2) EP2608796B1 (enExample)
JP (4) JP5918235B2 (enExample)
KR (2) KR20190022884A (enExample)
CN (2) CN107007615A (enExample)
AU (3) AU2011285490B2 (enExample)
CA (1) CA2803388C (enExample)
CY (1) CY1121419T1 (enExample)
DK (1) DK2608796T3 (enExample)
ES (1) ES2711622T3 (enExample)
HU (1) HUE043370T2 (enExample)
IL (2) IL224487A (enExample)
MX (1) MX356671B (enExample)
NZ (1) NZ606250A (enExample)
PL (1) PL2608796T3 (enExample)
PT (1) PT2608796T (enExample)
RU (2) RU2017122482A (enExample)
SI (1) SI2608796T1 (enExample)
TR (1) TR201902439T4 (enExample)
WO (1) WO2012019165A2 (enExample)
ZA (1) ZA201300653B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2608796B1 (en) * 2010-08-05 2018-11-21 Seattle Genetics, Inc. Inhibition of protein fucosylation in vivo using fucose analogs
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
WO2014130613A2 (en) 2013-02-22 2014-08-28 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CN106699886A (zh) * 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
EA201891340A1 (ru) * 2015-12-04 2018-11-30 Сиэтл Дженетикс, Инк. Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
CN109072273B (zh) * 2016-05-10 2022-04-15 阿雷斯贸易股份有限公司 使用全乙酰基半乳糖调节重组蛋白的蛋白质半乳糖基化概况的方法
JP2018002666A (ja) * 2016-07-04 2018-01-11 国立研究開発法人理化学研究所 フコース類似体と糖を検出する方法
KR102687149B1 (ko) * 2017-06-07 2024-07-24 씨젠 인크. 감소된 표면 푸코실화를 갖는 t 세포 및 이를 생산하고 사용하는 방법
MX2020005662A (es) 2017-12-01 2020-08-20 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
WO2019190984A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
MA53434A (fr) 2018-08-23 2021-12-01 Seagen Inc Anticorps anti-tigit
US20220062315A1 (en) * 2018-12-27 2022-03-03 Keio University Anti-human norovirus agent
KR20220115998A (ko) * 2019-12-19 2022-08-19 메르크 파텐트 게엠베하 단백질의 글리코실화 프로파일을 조절하기 위한 방법 및 조성물
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗-cd70抗體治療癌症之方法
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
JP2023528400A (ja) * 2020-06-03 2023-07-04 サイモン フレイザー ユニヴァーシティー タンパク質フコシル化の阻害剤及びその用途
IL305883A (en) 2021-03-18 2023-11-01 Seagen Inc Selective release of drugs from internalized conjugates of biologically active compounds
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440780A (en) 1979-06-01 1984-04-03 Chevron Research Company Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones
JPH0660189B2 (ja) 1986-01-22 1994-08-10 財団法人微生物化学研究会 2,6−ジデオキシ−2−フルオロ−l−タロピラノ−ス又はその誘導体とその製造法
FR2630914A1 (fr) 1988-05-04 1989-11-10 Hoechst Sa Laboratoires Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments
KR100211417B1 (ko) 1990-11-30 1999-10-01 유충식 L-탈로피라노시드 유도체 및 그의 제조방법
US5461143A (en) 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5210078A (en) * 1991-04-30 1993-05-11 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
WO1993008205A1 (en) 1991-10-15 1993-04-29 The Scripps Research Institute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of gdp-fucose
EP0721956B1 (en) 1993-09-29 2000-08-02 Nissin Shokuhin Kabushiki Kaisha 21-substituted steroid compound
US5481143A (en) 1993-11-15 1996-01-02 Burdick; Brian K. Self starting brushless d.c. motor
FR2723947B1 (fr) 1994-08-31 1996-09-27 Adir Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6713287B1 (en) 1995-10-24 2004-03-30 The Scripps Research Institute Enzymatic synthesis of L-fucose and L-fucose analogs
WO1998018805A2 (en) * 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics
US5770407A (en) 1996-12-10 1998-06-23 The Scripps Research Institute Process for preparing nucleotide inhibitors of glycosyltransferases
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのppo阻害性除草剤耐性付与法
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
JPH1135593A (ja) 1997-07-18 1999-02-09 Daikin Ind Ltd 2−フルオロフコシル−n−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
KR20050098244A (ko) 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
DE602004028249D1 (de) 2003-06-18 2010-09-02 Chugai Pharmaceutical Co Ltd Fucosetransporter
CA2542130A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cell genomically modified to produce polypeptides with an altered glycosylation pattern
EP1699806A1 (en) 2003-12-23 2006-09-13 Progen Industries Limited Glycosaminoglycan (gag) mimetics
DE102004032421A1 (de) 2004-07-05 2006-01-26 Bayer Cropscience Ag Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
US7700321B2 (en) 2005-10-21 2010-04-20 Genzyme Corporation Antibody-based therapeutics with enhanced ADCC activity
DE602006017728D1 (de) 2005-11-28 2010-12-02 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose
WO2007071051A1 (en) * 2005-12-21 2007-06-28 Viventia Biotech Inc. Novel cancer-associated antigen
WO2007081031A1 (ja) 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
DK1991273T4 (da) 2006-02-10 2022-02-07 Life Technologies Corp Mærkning og påvisning af post-translationelt modificerede proteiner
BRPI0708273A2 (pt) 2006-02-24 2011-05-24 Univ Texas uso de compostos de hexoses
EP1991056A4 (en) 2006-02-24 2009-09-02 Univ Miami MANNOSEDERIVATES FOR THE KILLING OF TUMOR CELLS
EP1996609B1 (en) 2006-03-22 2016-08-03 The Scripps Research Institute Method of preparing glycopeptides
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
AU2007308983B2 (en) 2006-10-24 2012-12-06 Emergent Product Development Seattle, Llc A method for increasing antibody-dependent cytotoxicity with castanospermine
EP2457573A1 (en) 2007-02-09 2012-05-30 GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
CN101062939A (zh) 2007-05-17 2007-10-31 北京热景生物技术有限公司 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
US20110003338A1 (en) 2008-03-11 2011-01-06 Robert Bayer Antibodies with enhanced adcc function
CA2975228C (en) * 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009143078A2 (en) 2008-05-19 2009-11-26 Board Of Regents, The University Of Texas System Methods of treating brain cancer using hexose compounds
WO2009143515A2 (en) 2008-05-23 2009-11-26 University Of Miami Treatment using continuous low dose application of sugar analogs
CA2728344A1 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
WO2010111713A2 (en) 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
EP2566876A4 (en) * 2010-05-06 2014-01-08 Univ Fraser Simon METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES
US20110288880A1 (en) 2010-05-07 2011-11-24 Patient Care Automation Services, Inc. Targeted health care messaging
EP2608796B1 (en) * 2010-08-05 2018-11-21 Seattle Genetics, Inc. Inhibition of protein fucosylation in vivo using fucose analogs
US20120276108A1 (en) 2011-01-11 2012-11-01 Intertech Bio Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
US8979675B2 (en) 2012-04-25 2015-03-17 Nike, Inc. Golf ball core having radial appendages
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
EA201891340A1 (ru) 2015-12-04 2018-11-30 Сиэтл Дженетикс, Инк. Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек

Similar Documents

Publication Publication Date Title
JP2013541503A5 (enExample)
RU2013109415A (ru) Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
JP2018504437A5 (enExample)
JP6100439B2 (ja) アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法
RU2012110380A (ru) Новое производное 5-фторурацила
JP2016515096A5 (enExample)
JP2018530549A5 (enExample)
JP2008511634A5 (enExample)
JP2012503621A5 (enExample)
RU2016125213A (ru) Нуклеотиды для лечения рака печени
RU2015107733A (ru) Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения
JP2015535831A5 (enExample)
JP2015180657A5 (enExample)
JP2007269797A5 (enExample)
RU2009107537A (ru) Новые стероидные соединения, обладающие повышенной растворимостью в воде и устойчивостью к метаболизму, и способы их приготовления
JP2019522055A5 (enExample)
JP2012519691A5 (enExample)
RU2012136468A (ru) Производные фуро[3,2,-в]пирана, применимые в синтезе аналогов
RU2012117829A (ru) Фосфорамидатные производные нуклеозидов
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2019510027A5 (enExample)
JP2017519754A5 (enExample)
JP2015508092A5 (enExample)
JP2014519488A5 (enExample)
RU2012150501A (ru) Противораковые стероидные лактоны, ненасыщенные в положении 7(8)